© 1995 American Heart Association, Inc.
Articles |
c-myc in Vasculoproliferative Disease
From Harvard University–Massachusetts Institute of Technology, Division of Health Sciences and Technology (E.R.E.), Cambridge; the Department of Medicine (E.R.E., M.S., R.D.R.), Harvard Medical School, Boston, Mass; and the Department of Biology (M.S., M.G.S., R.D.R.), Massachusetts Institute of Technology, Cambridge.
Abstract Antisense oligonucleotides to genes central to cellular proliferation have suppressed smooth muscle cell growth in vitro and in vivo. We now report that although the response of cultured smooth muscle cells to antisense oligonucleotides to c-myc and c-myb is identical, the response of the injured arterial wall to these oligomers depends on the kinetics of gene expression and oligonucleotide delivery. Two different antisense oligonucleotides to each oncogene were administered to the perivascular aspect of injured rat carotid arteries via polymer-based delivery systems. The acute release of antisense oligonucleotides from the Pluronic gels reduced in vitro cell growth 54.8% with c-myc and 56.9% with c-myb. The more sustained release from ethylene vinyl acetate copolymer (EVAc) matrices was slightly less efficient, inhibiting proliferation 47.3% and 43.3%, respectively. However, although both EVAc and Pluronic release of c-myb antisense oligonucleotide sequences inhibited intimal hyperplasia 2 weeks after injury, only the more prolonged EVAc matrix release of antisense oligonucleotide to c-myc was effective. The failure of the short course of c-myc oligomer release from Pluronic gels stemmed from early successful suppression with late loss of regulation and not from inactivation of the antisense oligonucleotide within the polymeric gel. Within 24 hours of injury, Pluronic-based release of c-myc antisense oligomers reduced mRNA levels in the tunica media 2.5-fold and immunocytochemical identification of c-myc expression by 98.8%. As a result, the number of proliferating cells was decreased 6.5-fold 3 days after injury. One week after injury, however, the effect of Pluronic gel–released c-myc antisense was lost on both the number of cells expressing the oncogene (only 29.6% suppression) and the extent of intimal hyperplasia (intimal-to-medial area ratio, 0.35±0.02 versus 0.5±0.1 in control arteries). In contrast, EVAc release of the same sequences obliterated protein expression, maintaining a 99.6±0.7% inhibition for the duration of the experiment, and reduced intimal hyperplasia 2 weeks after injury 11.1-fold. We conclude that the effectiveness of the antisense approach to suppression of neointimal proliferation depends on the time course of expression of the target gene as well as the kinetics of oligonucleotide delivery.
Key Words: antisense oligonucleotides • c-myb • c-myc • restenosis • polymer-based drug delivery
This article has been cited by other articles:
 |
|
 |
|
  K. S. Ramos H-RAS Controls Phenotypic Profiles of Vascular Smooth Muscle Cells and the Pathogenesis of Vascular Proliferative Disorders Circ. Res., May 22, 2009; 104(10): 1139 - 1141. [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, J. Zheng, X. Bai, B. Liu, C.-j. Liu, Q. Xu, Y. Zhu, N. Wang, W. Kong, and X. Wang ADAMTS-7 Mediates Vascular Smooth Muscle Cell Migration and Neointima Formation in Balloon-Injured Rat Arteries Circ. Res., March 13, 2009; 104(5): 688 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Forte, S. Esposito, M. De Feo, U. Galderisi, C. Quarto, F. Esposito, A. Renzulli, L. Berrino, M. Cipollaro, L. Agozzino, et al. Stenosis progression after surgical injury in Milan hypertensive rat carotid arteries Cardiovasc Res, December 1, 2003; 60(3): 654 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hilker, T. Langin, U. Hake, F.-X. Schmid, W. Kuroczynski, H.-A. Lehr, H. Oelert, and M. Buerke Gene expression profiling of human stenotic aorto-coronary bypass grafts by cDNA array analysis Eur. J. Cardiothorac. Surg., April 1, 2003; 23(4): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Ghosh, L. Gadiparthi, Z.-Z. Zeng, M. Bhanoori, C. Tellez, M. Bar-Eli, and G. N. Rao ATF-1 Mediates Protease-activated Receptor-1 but Not Receptor Tyrosine Kinase-induced DNA Synthesis in Vascular Smooth Muscle Cells J. Biol. Chem., June 7, 2002; 277(24): 21325 - 21331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Kipshidze, H.-S. Kim, P. Iversen, H. A. Yazdi, B. Bhargava, G. New, R. Mehran, F. Tio, C. Haudenschild, G. Dangas, et al. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1686 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Marchand, N. Noiseux, J.-F. Tanguay, and M. G. Sirois Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H194 - H204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074. [PDF]
|
|
|
|
 |
|
 I. Fishbein, M. Chorny, S. Banai, A. Levitzki, H. D. Danenberg, J. Gao, X. Chen, E. Moerman, I. Gati, V. Goldwasser, et al. Formulation and Delivery Mode Affect Disposition and Activity of Tyrphostin-Loaded Nanoparticles in the Rat Carotid Model Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1434 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Lou, K. L. Garrett, P. E. Rakoczy, and T. V. Chirila Synthetic Hydrogels as Carriers in Antisense Therapy: Preliminary Evaluation of an Oligodeoxynucleotide Covalent Conjugate with a Copolymer of 1-Vinyl-2-Pyrrolidinone and 2-Hydroxyethyl Methacrylate J Biomater Appl, April 1, 2001; 15(4): 307 - 320. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Noiseux, C. H. Boucher, R. Cartier, and M. G. Sirois Bolus Endovascular PDGFR-{beta} Antisense Treatment Suppressed Intimal Hyperplasia in a Rat Carotid Injury Model Circulation, September 12, 2000; 102(11): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Fishbein, J. Waltenberger, S. Banai, L. Rabinovich, M. Chorny, A. Levitzki, A. Gazit, R. Huber, U. Mayr, S. D. Gertz, et al. Local Delivery of Platelet-Derived Growth Factor Receptor-Specific Tyrphostin Inhibits Neointimal Formation in Rats Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 667 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Bernatchez, S. Soker, and M. G. Sirois Vascular Endothelial Growth Factor Effect on Endothelial Cell Proliferation, Migration, and Platelet-activating Factor Synthesis Is Flk-1-dependent J. Biol. Chem., October 22, 1999; 274(43): 31047 - 31054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Johnson and G. K. Owens Differential activation of the SMalpha A promoter in smooth vs. skeletal muscle cells by bHLH factors Am J Physiol Cell Physiol, June 1, 1999; 276(6): C1420 - C1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Topol and P. W. Serruys Frontiers in Interventional Cardiology Circulation, October 27, 1998; 98(17): 1802 - 1820. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lopez, E. R. Edelman, A. Stamler, M. G. Hibberd, P. Prasad, K. A. Thomas, J. Disalvo, R. P. Caputo, J. P. Carrozza, P. S. Douglas, et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia Am J Physiol Heart Circ Physiol, March 1, 1998; 274(3): H930 - H936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lundgren, B. Vinogradsky, A. Guala, and S. Fujii A Vitronectin Receptor Antagonist Inhibits Neointimal Formation After Balloon Arterial Injury in Rabbits in Vivo Vascular and Endovascular Surgery, January 1, 1998; 32(1): 47 - 53. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Bennett, V. Lindner, D. DeBlois, M. A. Reidy, and S. M. Schwartz Effect of Phosphorothioated Oligonucleotides on Neointima Formation in the Rat Carotid Artery : Dissecting the Mechanism of Action Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2326 - 2332. [Abstract] [Full Text]
|
|
|
|
|
|
M. G. Sirois, M. Simons, D. J. Kuter, R. D. Rosenberg, and E. R. Edelman Rat Arterial Wall Retains Myointimal Hyperplastic Potential Long After Arterial Injury Circulation, August 19, 1997; 96(4): 1291 - 1298. [Abstract] [Full Text]
|
|
|
|
|
|
J. Gunn, C. M. Holt, S. E. Francis, L. Shepherd, M. Grohmann, C. M. H. Newman, D. C. Crossman, and D. C. Cumberland The Effect of Oligonucleotides to c-myb on Vascular Smooth Muscle Cell Proliferation and Neointima Formation After Porcine Coronary Angioplasty Circ. Res., April 19, 1997; 80(4): 520 - 531. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. L. Cioffi, M. Garay, J. F. Johnston, K. McGraw, R. T. Boggs, D. Hreniuk, and B. P. Monia Selective Inhibition of A-Raf and C-Raf mRNA Expression by Antisense Oligodeoxynucleotides in Rat Vascular Smooth Muscle Cells: Role of A-Raf and C-Raf in Serum-Induced Proliferation Mol. Pharmacol., March 1, 1997; 51(3): 383 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Sirois, M. Simons, and E. R. Edelman Antisense Oligonucleotide Inhibition of PDGFR-ß Receptor Subunit Expression Directs Suppression of Intimal Thickening Circulation, February 4, 1997; 95(3): 669 - 676. [Abstract] [Full Text]
|
|
|
|
|
|
A. B. Firulli, J. M. Miano, W. Bi, A. D. Johnson, W. Casscells, E. N. Olson, and J. J. Schwarz Myocyte Enhancer Binding Factor-2 Expression and Activity in Vascular Smooth Muscle Cells : Association With the Activated Phenotype Circ. Res., February 1, 1996; 78(2): 196 - 204. [Abstract] [Full Text]
|
|